FDA issued a letter to Bayer outlining conditions for submitting additional postmarket information to the agency about Essure. The letter applies to reportable adverse events Bayer is or becomes aware of from social media data received in relation to litigation.
from FDA Press Releases RSS Feed https://ift.tt/2S2Ubng
via IFTTT
No comments:
Post a Comment